Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 11 recruiting now early-phase tilt

End-Stage Kidney Disease: early-phase trial registry

11 of 21 indexed End-Stage Kidney Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #797 of 28,707 conditions by registered trial count.

21 US clinical trials · 11 currently recruiting · #797 of 28,707 conditions by registered trial count

End-Stage Kidney Disease: 21 US clinical trials tracked, 11 recruiting.

End-Stage Kidney Disease is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Diality, running 2 of these trials.

Enrollment posture brief

Registry condition end-stage-kidney-disease

OPEN 11 | RECR 52% | LATE 2 | EARLY 6 | RANK #797 | SPON 2

Nearest open-share peer: Hearing Loss, Sensorineural (52% recruiting · 21 trials)

End-Stage Kidney Disease (th…52%Anal Cancer42.9%Allergic Conjunctivitis14.3%Attention Deficit Disorder W4.8%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near End-Stage Kidney Disease

End-Stage Kidney Disease lists 11 open slots (52% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for End-Stage Kidney Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. End-Stage Kidney Disease is recruiting above its size-band peers.

    11 of 21 indexed trials (52.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of End-Stage Kidney Disease trials is spread across many organizations.

    Diality accounts for 2 of 21 trials (9.5%). 18 distinct sponsors appear on at least one study for this condition label.

  3. Typical End-Stage Kidney Disease enrolment sits around 100 participants.

    Median target enrolment is 100 among the 21 trials that report a genuine target (sentinel values excluded). 10 of those (47.6%) plan for fewer than 100 participants.

  4. End-Stage Kidney Disease research is mostly interventional.

    19 interventional and 2 observational studies make up this index (90.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 22Phase 32

Open and recent trials

21 total, page 1 of 1

RECRUITING Phase 3 2,540 participants

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

VA Office of Research and Development

NCT05931276

RECRUITING NA 2,400 participants

Symptom Monitoring in Hemodialysis

University of Pennsylvania

NCT05738330

RECRUITING Phase 2 2,310 participants

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

CSL Behring

NCT05485961

RECRUITING NA 350 participants

Incremental Hemodialysis: The TwoPlus Trial

Wake Forest University Health Sciences

NCT05828823

RECRUITING 200 participants

Duke APOL1 Research Biorepository

Duke University

NCT04160507

RECRUITING NA 125 participants

Pain Reduction Using NEurostimulation Study

Weill Medical College of Cornell University

NCT05311956

RECRUITING NA 100 participants

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

Hennepin Healthcare Research Institute

NCT05879302

RECRUITING NA 50 participants

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

Diality

NCT06613568

RECRUITING Phase 1 28 participants

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

Eli Lilly and Company

NCT07426380

RECRUITING NA 20 participants

Staged Kidney Transplantation During Combined Heart/Kidney Transplantation

Cedars-Sinai Medical Center

NCT06877169

RECRUITING Phase 1 10 participants

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

University of California, Los Angeles

NCT05525507

ACTIVE NOT RECRUITING NA 103 participants

The Arteriovenous Vascular (AV) ACCESS Trial

Wake Forest University Health Sciences

NCT04646226

ACTIVE NOT RECRUITING NA 61 participants

Virtual Reality in Hemodialysis to Improve Psychological Well-being

University of Illinois at Urbana-Champaign

NCT05642364

ACTIVE NOT RECRUITING Phase 1 16 participants

Immunological Tolerance in Patients With Mismatched Kidney Transplants

University of California, Los Angeles

NCT05806749

COMPLETED Phase 2 506 participants

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

Merck Sharp & Dohme

NCT05027074

COMPLETED Phase 3 269 participants

Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes

Vascular Therapies

NCT02513303

COMPLETED NA 103 participants

Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD

Medtronic Endovascular

NCT02363972

COMPLETED Phase 1 62 participants

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

University of Utah

NCT05614115

COMPLETED NA 40 participants

Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes

Emory University

NCT05741489

COMPLETED NA 12 participants

First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings

Diality

NCT06581393

COMPLETED 10 participants

Blood Volume Analysis and Related Outcomes in Hemodialysis

VA New York Harbor Healthcare System

NCT01679249

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 2

Named interventions

Most-linked intervention names on End-Stage Kidney Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
Sirolimus-eluting Collagen Implant (SeCI) Device
1 trials
AV Fistula Surgery Procedure
1 trials
Moda-flx Hemodialysis System Device
1 trials
Ellipsys Vascular Access Catheter Device
1 trials
MK-2060 Drug
1 trials
surgical intervention for creation of a fistula Procedure
1 trials
AV graft Device
1 trials

US sites by state

Facility locations filed on End-Stage Kidney Disease trials. A trial with sites in several states counts in each.

California 11 trials
Arizona 4 trials
Alabama 4 trials
New York 3 trials
North Carolina 3 trials
Massachusetts 3 trials
Georgia 3 trials
Florida 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this End-Stage Kidney Disease page

21 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 11 End-Stage Kidney Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Diality sponsors the most End-Stage Kidney Disease trials on record, review their full trial history before evaluating a specific study. See Diality's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This End-Stage Kidney Disease condition card totals 21 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.